218. Alport syndrome Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 30 / Drugs : 36 - (DrugBank : 15) / Drug target genes : 8 - Drug target pathways : 46
Alport syndrome and other diseases between which drug repositioning (DR) might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Score (Drug repositionability)
| ID | Diseases (Sorted by score) | Score |
|---|---|---|
| 218 | Alport syndrome | - |
| 66 | IgA nephropathy | 4.286 |
| 222 | Primary nephrotic syndrome | 4.235 |
| 86 | Pulmonary arterial hypertension | 4.208 |
| 67 | Polycystic kidney disease | 2.807 |
| 58 | Hypertrophic cardiomyopathy | 2.778 |
| 113 | Muscular dystrophy | 2.757 |
| 97 | Ulcerative colitis | 2.704 |
| 96 | Crohn disease | 2.698 |
| 46 | Malignant rheumatoid arthritis | 2.695 |
| 6 | Parkinson disease | 2.695 |
| 210 | Single Ventricle | 1.641 |
| 271 | Ankylosing spondylitis | 1.610 |
| 17 | Multiple system atrophy | 1.574 |
| 75 | Cushing disease | 1.573 |
| 19 | Lysosomal storage disease | 1.565 |
| 84 | Sarcoidosis | 1.555 |
| 299 | Cystic fibrosis | 1.547 |
| 85 | Idiopathic interstitial pneumonia | 1.545 |
| 51 | Scleroderma | 1.540 |
| 49 | Systemic lupus erythematosus | 1.539 |
| 13 | Multiple sclerosis/Neuromyelitis optica | 1.517 |